Trust Size
$99M
Peak Price
$210.00
Current Price
$25.24
Return
+152.4%
Price Journey
What Happened
Surrozen is a clinical-stage biotech company developing antibody-based therapies that selectively activate the Wnt signaling pathway for tissue repair and regeneration.
Surrozen went public in 2022 through a merger with Consonance-HFW Acquisition Corp, a SPAC sponsored by Consonance Capital Management. The company is pioneering Wnt biology to develop treatments for liver, intestinal, and retinal diseases where tissue regeneration is needed. Surrozen has advanced multiple programs into clinical trials, and the stock has performed relatively well for a clinical-stage biotech SPAC.
Timeline
2020-10-26
S-1 Registration Filed
2021-07-15
Merger Proxy Filed (DEFM14A)
🔀 Reverse Stock Split
Reverse split ratio: . Reverse splits are used to avoid delisting but destroy shareholder value through the illusion of a higher stock price.
SEC Filing Details
CIK Number
1824893
Total SEC Filings
444
State of Incorporation
DE
Last Filing Date
2026-03-16
Business Location
Princeton, NJ
Trust/Asset Size
$99M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for Surrozen, Inc.